Masimo Corporation (MASI)
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept.
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership
MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.
Google Launches Smartwatch Pact With MedTech Firm Masimo
After tangling in court with Apple over smartwatch features, medical technology company Masimo is teaming with Google. The company announced in a news release Saturday (Sept.
Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte
Chicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical ISRG, Masimo Corp. MASI and Veracyte, Inc. VCYT.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
Masimo CEO shared confidential information with investor ahead of public release, court filing shows
Masimo CEO Joe Kiani revealed what he called material non-public information to a major investor in March, 12 hours before it was released to the public, according to court filings. The documents, partially unsealed on Friday, are related to ongoing litigation between Politan and Masimo.
Does Masimo (MASI) Have the Potential to Rally 27.46% as Wall Street Analysts Expect?
The mean of analysts' price targets for Masimo (MASI) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Masimo, under activist pressure, subpoenaed two top proxy advisors for private investor communications
Medical device company Masimo took the unusual step of subpoenaing Glass Lewis and ISS for their private communications with shareholders about Masimo's upcoming proxy fight with activist investor Politan Capital. Politan's Quentin Koffey is on Masimo's board and has launched a proxy fight that would let his firm fill two further seats.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
What Makes Masimo (MASI) a New Buy Stock
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
